Severe ocular abnormalities in C57BL/6 but not in 129/Sv p53-deficient mice

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 8, 1999, Pages 1874-1878

  Ikeda, Sakae ^a   Hawes, Norman L ^a   Chang, Bo ^a   Avery, Cindy S ^a   Smith, Richard S ^a   Nishina, Patsy M ^a  

^a JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EYE MALFORMATION; GENE DISRUPTION; GENE MUTATION; GENETIC ANALYSIS; MOUSE; NONHUMAN; OPTIC NERVE; OPTIC NERVE HYPOPLASIA; PHENOTYPE; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA FOLD; VITREOUS OPACITY;

ABNORMALITIES, MULTIPLE; ANIMALS; CATARACT; DNA PRIMERS; EYE ABNORMALITIES; EYE DISEASES; FEMALE; GENES, P53; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; OPTIC NERVE; PHENOTYPE; RETINA; RETINAL DYSPLASIA; TUMOR SUPPRESSOR PROTEIN P53; VITREOUS BODY;

EID: 0033056621     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
2. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10: 1054-1072.
3. Hall PA, Lane DP. Tumour suppressors: a developing role for p53? Curr Biol. 1997;7:R144-R147.
4. Bouck N. P53 and angiogenesis. Biochim Biophys Acta. 1996; 1287:63-66.
5. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215-221.
6. Jacks R, Remington L. Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;4:1-7.
7. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet. 1995;10:175-187.
8. Smith RS, Rudt LA. Ultrastructural studies of the blood-aqueous barrier. Am J Ophthalmol. 1973;76:937-947.
9. Goldberg MF. Persistent fetal vasculature (PFV): An integrated interpretation of signs and symptoms associated with persistent hyperplastic primary vitreous (PHPV). Am J Ophthalmol. 1997; 124:587-626.
10. Stone U, Dreher Z. Relationship between astrocytes, ganglion cells and vasculature in the retina. J Comp Neurol. 1987;225:35-49.
11. Clarke AR, Gledhill S, Hooper ML, Bird CC, Wyllie AH. p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma irradiation. Oncogene. 1994;9:1767-1773.
12. Howes KA, Ransom N, Papermaster DS, Lasudry JGH, Albert DM, Windle JJ. Apoptosis or retinoblastoma: alternative fates of photo-receptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev. 1994;8:1300-1310.
13. Reichel MB, Ali RR, D'Esposito F, et al. High frequency of persistent hyperplastic primary vitreous and cataracts in p53-dencient mice. Cell Death Diff. 1998;5:156-162.
14. Kastan MB, Zhan Q, elDeiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-tellangiectasia. Cell. 1992;71:587-597.
15. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9:1799-1805.
16. Gariano RF, Kalina RE, Hendrickson AE. Normal and pathological mechanisms in retinal vascular development. Surv Ophthalmol. 1996;40:481-490.
17. Stellmach V, Volpert OV, Crawford SE, Lawler J, Hynes RO, Bouck N. Tumour suppressor genes and angiogenesis: The role of p53 in fibroblasts. Eur J Cancer. 1996;32A:2394-2400.
18. Brouwer B, Zeeman WPC. The projection of the retina in the primary optic neuron in monkeys. Brain. 1926;49:1-11.